Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

MEGA-9

Copy Product Info
😃Good
Catalog No. T20992Cas No. 85261-19-4
Alias Nonanoyl-N-Methylglucamide

MEGA-9 (Nonanoyl-N-Methylglucamide) solubilizes membrane protein and can be used as a nonionic detergent.

MEGA-9

MEGA-9

Copy Product Info
😃Good
Purity: 99.9%
Catalog No. T20992Alias Nonanoyl-N-MethylglucamideCas No. 85261-19-4
MEGA-9 (Nonanoyl-N-Methylglucamide) solubilizes membrane protein and can be used as a nonionic detergent.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
100 mg$29-In Stock
1 mL x 10 mM (in DMSO)$29-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.9%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

MEGA-9 AI Summary
MEGA-9 exhibits significant antiviral activity against various strains of HIV1, notably inhibiting HIV1 NL4.3 in human MT4 cells with an IC50 of 0.0023 μg/mL and an EC90 of 44.0 ng/mL. It also demonstrates activity against HIV1 3B in human HOS cells (IC50 of 10.0 nM) and other HIV1 strains with EC50 values ranging from 15.0 nM to greater than 200.0 nM. Additionally, it targets the CXCR4 receptor with an IC50 of 13.0 nM, showing low binding affinity for other chemokine receptors. Pharmacokinetically, the compound displays good oral bioavailability in dogs (80.0%), high permeability (86.0 nm/s at pH 7.4), and a moderate stability in human liver microsomes (67.0% at 0.5 μM). Moreover, MEGA-9 interacts with cytochrome P450 enzymes, inhibiting CYP2C19 (20% inhibition), CYP2D6 (IC50 of 1600-1640.0 nM), and CYP3A4 (35% inhibition). It has a high intrinsic clearance rate in rat liver microsomes and is rapidly metabolized and eliminated from the system. In addition to its antiviral properties, MEGA-9 also shows inhibitory effects on human HDAC6 enzyme activity and possesses moderate affinity for the CXCR4 receptor (Ki of 23.0 nM). However, its activity against SARS-CoV-2 and other viral infections appears limited, with low inhibition percentages observed against SARS-CoV-2 induced cytotoxicity. The compound exhibits systemic pharmacokinetic parameters such as changes in Cmax, AUC, and clearance rates when combined with ritonavir, suggesting potential drug-drug interactions. Oral bioavailability in mice is low (2.4%-2.54%), with a maximum plasma concentration of 117.32 nM at an oral dose of 30 mg/kg. These diverse bioactivities and pharmacokinetic properties highlight MEGA-9 as a compound of interest for further drug development and antiviral research..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
MEGA-9 (Nonanoyl-N-Methylglucamide) solubilizes membrane protein and can be used as a nonionic detergent.
SynonymsNonanoyl-N-Methylglucamide
Chemical Properties
Molecular Weight335.44
FormulaC16H33NO6
Cas No.85261-19-4
SmilesCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Relative Density.1.172 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 3.36 mg/mL (10.02 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.9812 mL14.9058 mL29.8116 mL149.0580 mL
5 mM0.5962 mL2.9812 mL5.9623 mL29.8116 mL
10 mM0.2981 mL1.4906 mL2.9812 mL14.9058 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy MEGA-9 | purchase MEGA-9 | MEGA-9 cost | order MEGA-9 | MEGA-9 chemical structure | MEGA-9 formula | MEGA-9 molecular weight